Antioxidant approaches for the treatment of Alzheimer’s disease

Oxidative stress is an important factor, and one that acts in the earliest stages, of Alzheimer’s disease (AD) pathogenesis. The reduction of oxidative stress has been tested as a therapy for AD. While the trial of vitamin E supplementation in moderately severe AD is the most promising so far, it also reveals the limitations of general antioxidant therapies that simply lower oxidative stress and, therefore, the complexity of the redox system. The multiple contributing factors that foster the clinical manifestations of AD should be considered when designing antioxidative stress therapy. In this article, we discuss the multiple pathogenic mechanisms of oxidative stress in AD and the potential targeting approaches.

[1]  J. Paskavitz,et al.  Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension , 2009, American journal of Alzheimer's disease and other dementias.

[2]  Eric Klann,et al.  Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[3]  Xiongwei Zhu,et al.  Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins , 2008, Proceedings of the National Academy of Sciences.

[4]  Lewis H Kuller,et al.  Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.

[5]  G. McKhann,et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.

[6]  Xiongwei Zhu,et al.  Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. , 2008, The American journal of pathology.

[7]  M. Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[8]  P. Crane,et al.  Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults , 2008, Journal of the American Geriatrics Society.

[9]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[10]  G. Perry,et al.  Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-β peptide , 2007 .

[11]  G. Perry,et al.  Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. , 2007, Biochemistry.

[12]  P. Singal,et al.  Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications , 2007, Cell Biochemistry and Biophysics.

[13]  A. Nunomura,et al.  Autophagocytosis of mitochondria is prominent in Alzheimer disease , 2007, Journal of the Neurological Sciences.

[14]  J. Trnka,et al.  Mitochondrial targeting of quinones: therapeutic implications. , 2007, Mitochondrion.

[15]  George Perry,et al.  Alzheimer disease, the two-hit hypothesis: an update. , 2007, Biochimica et biophysica acta.

[16]  Robin A. J. Smith,et al.  Targeting antioxidants to mitochondria by conjugation to lipophilic cations. , 2007, Annual review of pharmacology and toxicology.

[17]  Mark A. Smith,et al.  Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance , 2006, Neuroscience Letters.

[18]  N. Vaziri,et al.  Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension , 2006, Nature Clinical Practice Nephrology.

[19]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[20]  J. Simard,et al.  Recommendations of the National Heart, Lung, and Blood Institute Working Group on Cerebrovascular Biology and Disease , 2006, Stroke.

[21]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[22]  Hyoung-Gon Lee,et al.  Neuropathology of Alzheimer disease: pathognomonic but not pathogenic , 2006, Acta Neuropathologica.

[23]  P. Reddy,et al.  Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics , 2006, Journal of biomedicine & biotechnology.

[24]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[25]  M. W. Anders,et al.  Targeting antioxidants to mitochondria: a new therapeutic direction. , 2006, Biochimica et biophysica acta.

[26]  Hyoung-Gon Lee,et al.  Amyloid beta: the alternate hypothesis. , 2006, Current Alzheimer research.

[27]  M. Beal,et al.  Are mitochondria critical in the pathogenesis of Alzheimer's disease? , 2005, Brain Research Reviews.

[28]  Robin A. J. Smith,et al.  Synthesis and Characterization of a Triphenylphosphonium-conjugated Peroxidase Mimetic , 2005, Journal of Biological Chemistry.

[29]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[30]  A. M. James,et al.  Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species , 2005, Journal of Biological Chemistry.

[31]  Hyoung-Gon Lee,et al.  Tau phosphorylation in Alzheimer's disease: pathogen or protector? , 2005, Trends in molecular medicine.

[32]  R. Touyz Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? , 2004, Hypertension.

[33]  E. Schiffrin,et al.  Reactive oxygen species in vascular biology: implications in hypertension , 2004, Histochemistry and Cell Biology.

[34]  H. Szeto,et al.  Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury* , 2004, Journal of Biological Chemistry.

[35]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[36]  Eric J Topol,et al.  Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.

[37]  A. Mooradian,et al.  Recent trials of antioxidant therapy: what should we be telling our patients? , 2004, Cleveland Clinic journal of medicine.

[38]  Xiongwei Zhu,et al.  Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.

[39]  J. Trojanowski,et al.  Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  E. R. Taylor,et al.  Superoxide Activates Uncoupling Proteins by Generating Carbon-centered Radicals and Initiating Lipid Peroxidation , 2003, Journal of Biological Chemistry.

[41]  S. O. Bachurin,et al.  Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons , 2003, Bulletin of Experimental Biology and Medicine.

[42]  G. Oxenkrug,et al.  Mitochondria as a Target for Neurotoxins and Neuroprotective Agents , 2003, Annals of the New York Academy of Sciences.

[43]  Xiongwei Zhu,et al.  Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? , 2002, Free radical biology & medicine.

[44]  George Perry,et al.  Role of mitochondrial dysfunction in Alzheimer's disease , 2002, Journal of neuroscience research.

[45]  J. Joseph,et al.  Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain , 2002 .

[46]  J. Witteman,et al.  Dietary intake of antioxidants and risk of Alzheimer disease. , 2002, JAMA.

[47]  Xiongwei Zhu,et al.  Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.

[48]  S. Bachurin,et al.  Dimebon and Tacrine Inhibit Neurotoxic Action of β-Amyloid in Culture and Block L-type Ca2+ Channels , 2001, Bulletin of Experimental Biology and Medicine.

[49]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[50]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[51]  E. Giacobini Cholinesterase Inhibitors Stabilize Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[52]  S. Melov,et al.  Extension of life-span with superoxide dismutase/catalase mimetics. , 2000, Science.

[53]  J B Schulz,et al.  Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.

[54]  N. Vaziri,et al.  Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. , 2000, Hypertension.

[55]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[56]  Mark A. Smith,et al.  In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.

[57]  R. L. Russell,et al.  Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. , 1999, Archives of biochemistry and biophysics.

[58]  S. Cuzzocrea,et al.  A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. , 1999, Science.

[59]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[60]  George Perry,et al.  RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[61]  D. Tribble Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and β-Carotene A Statement for Healthcare Professionals From the American Heart Association , 1999 .

[62]  S. Bondy,et al.  Promotion of transition metal-induced reactive oxygen species formation by β-amyloid , 1998, Brain Research.

[63]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  K. Gulya,et al.  The cholinergic system in Alzheimer's disease , 1997, Progress in Neurobiology.

[65]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[66]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[67]  M. Mattson,et al.  Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors , 1996, Nature Medicine.

[68]  W. Danysz,et al.  The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. , 1996, Neuroreport.

[69]  W. Danysz,et al.  Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion. , 1996, European journal of pharmacology.

[70]  C. Parsons,et al.  Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. , 1996, European journal of pharmacology.

[71]  Mark A. Smith,et al.  Radical AGEing in Alzheimer's disease , 1995, Trends in Neurosciences.

[72]  P. Jenner Oxidative damage in neurodegenerative disease , 1994, The Lancet.

[73]  B. Hyman,et al.  Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation , 1994, Journal of neuropathology and experimental neurology.

[74]  C. Parsons,et al.  Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) , 1993, Neuropharmacology.

[75]  D. McLachlan,et al.  Desferrioxamine and Alzheimer's Disease: Video Home Behavior Assessment of Clinical Course and Measures of Brain Aluminum , 1993, Therapeutic drug monitoring.

[76]  S. Kish,et al.  Brain α‐Ketoglutarate Dehydrotenase Complex Activity in Alzheimer's Disease , 1993 .

[77]  P. Whitehouse Cholinergic therapy in dementia , 1993, Acta neurologica Scandinavica. Supplementum.

[78]  A. Shetter,et al.  Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations , 1992 .

[79]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[80]  C. Miller,et al.  Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. , 1991, Molecular and chemical neuropathology.

[81]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[82]  C. Yates,et al.  Enzyme Activities in Relation to pH and Lactate in Postmortem Brain in Alzheimer‐Type and Other Dementias , 1990, Journal of neurochemistry.

[83]  D. Neary,et al.  Presynaptic Cholinergic Dysfunction in Patients with Dementia , 1983, Journal of neurochemistry.

[84]  D. Harman,et al.  Free Radical Theory of Aging: Inhibition of Amyloidosis in Mice by Antioxidants; Possible Mechanism * , 1976, Journal of the American Geriatrics Society.

[85]  D. Harman Aging: a theory based on free radical and radiation chemistry. , 1956, Journal of gerontology.

[86]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[87]  Mark A. Smith,et al.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy. , 2010, Methods in molecular biology.

[88]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[89]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[90]  J. Wesson Ashford,et al.  APOE genotype effects on alzheimer’s disease onset and epidemiology , 2007, Journal of Molecular Neuroscience.

[91]  B. Teter,et al.  ApoE-dependent plasticity in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[92]  E. Giacobini Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. , 2002, Journal of neural transmission. Supplementum.

[93]  J. Joseph,et al.  Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. , 2002, Free radical biology & medicine.

[94]  E. Giacobini Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer’s Disease? , 2001, CNS drugs.

[95]  D. Selkoe Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. , 2001, Journal of Alzheimer's disease : JAD.

[96]  R. Castellani,et al.  Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. , 1998, Journal of Alzheimer's disease : JAD.

[97]  D. Selkoe Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.

[98]  J. Lohr,et al.  Free radical involvement in neuropsychiatric illnesses. , 1995, Psychopharmacology bulletin.

[99]  Brown Ja,et al.  Free radical involvement in neuropsychiatric illnesses. , 1995 .

[100]  D. Bennett,et al.  Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study , 2022 .